Ribon therapeutics

Clinical-stage biotechnology company focused on developing therapeutics that target novel enzyme families activated under cellular stress conditions, which contribute to disease. Ribon Therapeutics differentiates itself by discovering and developing first-in-class small molecule inhibitors to block cancer cells' ability to survive under stress, aiming to provide effective treatments for patients with limited therapeutic options. The primary beneficiaries of Ribon Therapeutics' innovations are patients suffering from cancer and other diseases with limited treatment options.

Ribon therapeutics was discovered on August 2nd 2021 and it currently has a search volume of 260 with a growth of +100%.